Drug intelligence / Profile preview

SWT012

Development stage: Preclinical
Lead developer: Sidewinder Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SWT012 is a lead bispecific antibody-drug conjugate (ADC) being developed by Sidewinder Therapeutics for the treatment of solid tumors. It is designed to target specific receptor co-complexes found on cancer cells, a strategy intended to improve the therapeutic index by enhancing drug delivery to tumors while sparing normal tissues. The candidate is built using Synaffix's (a Lonza company) ADC technology platform, incorporating GlycoConnect for site-specific conjugation, HydraSpace for improved solubility and stability, and toxSYN payloads. Sidewinder Therapeutics plans to advance SWT012 into clinical trials in 2027.

Targets

RCC2 (Regulator of Chromosome Condensation 2)AMY (Pancreatic alpha-amylase)

Beyond the preview

Go deeper on SWT012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SWT012.

Explore the full profile